Akebia Therapeutics Inc. (AKBA) 8.67 $AKBA
InsiderInsights.com Daily Round Up 4/22/15: PAY, VEEV, AGCO, OPK
InsiderInsights - at Seeking Alpha - Fri Apr 24, 11:13AM CDT
KMI: 44.34 (-0.23), MNST: 141.78 (+1.42), GE: 26.80 (-0.05), ADRO: 36.00 (-0.39), GRIF: 32.30 (+0.18), AGCO: 48.31 (-0.56), ABDC: 13.75 (-0.08), GOOG: 565.06 (+18.06), OZRK: 39.42 (-0.43), VEEV: 27.17 (-0.24), DVA: 83.91 (+0.50), OPK: 14.83 (+0.17), CDTX: 15.10 (-0.05), AKBA: 8.67 (-0.08), EBIX: 29.77 (-0.21), PAY: 35.64 (-0.48), SCHW: 30.12 (-0.38), CRM: 67.83 (-0.64)
Akebia closes equity offering
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:13PM CDT
AKBA: 8.67 (-0.08)
Akebia Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Apr 22, 3:01PM CDT
Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced the closing of its public offering of 8,363,636 shares of common stock at a public offering price of $8.25 per share. This includes the exercise in full by the underwriters of their option to purchase 1,090,909 shares of common stock. The aggregate net proceeds to Akebia, after underwriting discounts and commissions and estimated offering expenses, are approximately $64.6 million. All of the shares of common stock were offered by Akebia.
AKBA: 8.67 (-0.08), MS: 37.36 (-0.02)
Nasdaq stocks posting largest volume increases
AP - Fri Apr 17, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
UNAM: 10.76 (+0.06), ENZN: 1.72 (+0.18), SPPR: 2.46 (+0.08), IDSA: 3.89 (+0.01), AKBA: 8.67 (-0.08), IPDN: 3.10 (+0.06), LCUT: 15.54 (-0.25), ATHX: 1.29 (-0.03), CZFC: 12.43 (+0.13), TORM: 6.45 (+0.22)
Akebia Therapeutics (AKBA) Stock Declines Following Pricing of Secondary Offering
at The Street - Fri Apr 17, 2:14PM CDT
Akebia Therapeutics (AKBA) shares are falling after the company announced the pricing of its secondary public offering at $8.25 per share.
AKBA: 8.67 (-0.08)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 8:21AM CDT
WUBA: 79.42 (+1.16), UNXL: 6.20 (-0.19), IGTE: 45.85 (-0.05), CHOP: 3.41 (-0.20), NVGN: 6.54 (-0.01), NBG: 1.23 (+0.06), IPDN: 3.10 (+0.06), ROSG: 3.72 (+0.06), AMCN: 4.95 (-0.05), NOW: 76.09 (-0.79), CE: 65.85 (+0.75), MAT: 30.20 (+1.28), AMD: 2.30 (-0.03), AKBA: 8.67 (-0.08), ATHX: 1.29 (-0.03), TASR: 29.67 (-0.01), DSCO: 1.24 (-0.02)
Akebia prices secondary equity offering
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 5:58AM CDT
AKBA: 8.67 (-0.08)
Akebia Therapeutics prices public offering at USD8.25 per share
M2 - Fri Apr 17, 5:47AM CDT
Biopharmaceutical company Akebia Therapeutics (Nasdaq:AKBA) stated on Thursday that it has priced its public offering of 7,272,727 common stock at USD8.25 per share.
AKBA: 8.67 (-0.08)
Akebia Therapeutics Prices Public Offering of Common Stock
Business Wire - Thu Apr 16, 8:07PM CDT
Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced the pricing of an underwritten public offering of 7,272,727 shares of common stock at a price to the public of $8.25 per share. The net proceeds of the offering are expected to be approximately $56.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Akebia. The offering is expected to close on April 22, 2015, subject to the satisfaction of customary closing conditions.
AKBA: 8.67 (-0.08), MS: 37.36 (-0.02)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HBNK: 22.21 (-0.41), EVOK: 6.56 (+0.05), ADXS: 23.34 (-0.27), PTX: 7.09 (-0.24), ANGI: 6.16 (-0.24), CDXS: 4.71 (-0.30), AKBA: 8.67 (-0.08), PCRX: 85.07 (+0.80), OTIC: 31.80 (-1.32)
Akebia initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:27PM CDT
AKBA: 8.67 (-0.08)
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
Business Wire - Tue Apr 14, 3:22PM CDT
Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced that it intends to offer to sell $60 million of shares of its common stock in an underwritten public offering. As part of this offering, Akebia Therapeutics, Inc. intends to grant the underwriters a 30-day option to purchase up to an additional $9 million of shares of its common stock.
AKBA: 8.67 (-0.08), MS: 37.36 (-0.02)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), ZSPH: 40.97 (-1.90), RPTP: 10.81 (+0.10), OPK: 14.83 (+0.17), AMGN: 167.91 (-1.26), RGLS: 17.49 (-0.80), AMAG: 60.01 (-0.34), AKBA: 8.67 (-0.08), KERX: 11.41 (-0.32)
Akebia Therapeutics (AKBA) in Focus: Stock Slumps 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:00AM CDT
Akebia Therapeutics' shares fell over 14% last day reversing the uptrend as the stock had gained around 9% from Mar 25 to Mar 31
ARQL: 2.12 (unch), AKBA: 8.67 (-0.08)
Akebia Therapeutics' (AKBA) CEO John Butler discusses the results of its Phase 2b study of AKB-6548CEO (Transcript)
SA Transcripts - at Seeking Alpha - Mon Mar 16, 2:24PM CDT
AKBA: 8.67 (-0.08)
InsiderInsights.com Daily Round Up 4/22/15: PAY, VEEV, AGCO, OPK
InsiderInsights - at Seeking Alpha - Fri Apr 24, 11:13AM CDT
KMI: 44.34 (-0.23), MNST: 141.78 (+1.42), GE: 26.80 (-0.05), ADRO: 36.00 (-0.39), GRIF: 32.30 (+0.18), AGCO: 48.31 (-0.56), ABDC: 13.75 (-0.08), GOOG: 565.06 (+18.06), OZRK: 39.42 (-0.43), VEEV: 27.17 (-0.24), DVA: 83.91 (+0.50), OPK: 14.83 (+0.17), CDTX: 15.10 (-0.05), AKBA: 8.67 (-0.08), EBIX: 29.77 (-0.21), PAY: 35.64 (-0.48), SCHW: 30.12 (-0.38), CRM: 67.83 (-0.64)
Akebia closes equity offering
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:13PM CDT
AKBA: 8.67 (-0.08)
Akebia Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Apr 22, 3:01PM CDT
Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced the closing of its public offering of 8,363,636 shares of common stock at a public offering price of $8.25 per share. This includes the exercise in full by the underwriters of their option to purchase 1,090,909 shares of common stock. The aggregate net proceeds to Akebia, after underwriting discounts and commissions and estimated offering expenses, are approximately $64.6 million. All of the shares of common stock were offered by Akebia.
AKBA: 8.67 (-0.08), MS: 37.36 (-0.02)
Nasdaq stocks posting largest volume increases
AP - Fri Apr 17, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
UNAM: 10.76 (+0.06), ENZN: 1.72 (+0.18), SPPR: 2.46 (+0.08), IDSA: 3.89 (+0.01), AKBA: 8.67 (-0.08), IPDN: 3.10 (+0.06), LCUT: 15.54 (-0.25), ATHX: 1.29 (-0.03), CZFC: 12.43 (+0.13), TORM: 6.45 (+0.22)
Akebia Therapeutics (AKBA) Stock Declines Following Pricing of Secondary Offering
at The Street - Fri Apr 17, 2:14PM CDT
Akebia Therapeutics (AKBA) shares are falling after the company announced the pricing of its secondary public offering at $8.25 per share.
AKBA: 8.67 (-0.08)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 8:21AM CDT
WUBA: 79.42 (+1.16), UNXL: 6.20 (-0.19), IGTE: 45.85 (-0.05), CHOP: 3.41 (-0.20), NVGN: 6.54 (-0.01), NBG: 1.23 (+0.06), IPDN: 3.10 (+0.06), ROSG: 3.72 (+0.06), AMCN: 4.95 (-0.05), NOW: 76.09 (-0.79), CE: 65.85 (+0.75), MAT: 30.20 (+1.28), AMD: 2.30 (-0.03), AKBA: 8.67 (-0.08), ATHX: 1.29 (-0.03), TASR: 29.67 (-0.01), DSCO: 1.24 (-0.02)
Akebia prices secondary equity offering
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 5:58AM CDT
AKBA: 8.67 (-0.08)
Akebia Therapeutics prices public offering at USD8.25 per share
M2 - Fri Apr 17, 5:47AM CDT
Biopharmaceutical company Akebia Therapeutics (Nasdaq:AKBA) stated on Thursday that it has priced its public offering of 7,272,727 common stock at USD8.25 per share.
AKBA: 8.67 (-0.08)
Akebia Therapeutics Prices Public Offering of Common Stock
Business Wire - Thu Apr 16, 8:07PM CDT
Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced the pricing of an underwritten public offering of 7,272,727 shares of common stock at a price to the public of $8.25 per share. The net proceeds of the offering are expected to be approximately $56.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Akebia. The offering is expected to close on April 22, 2015, subject to the satisfaction of customary closing conditions.
AKBA: 8.67 (-0.08), MS: 37.36 (-0.02)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HBNK: 22.21 (-0.41), EVOK: 6.56 (+0.05), ADXS: 23.34 (-0.27), PTX: 7.09 (-0.24), ANGI: 6.16 (-0.24), CDXS: 4.71 (-0.30), AKBA: 8.67 (-0.08), PCRX: 85.07 (+0.80), OTIC: 31.80 (-1.32)
Akebia initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:27PM CDT
AKBA: 8.67 (-0.08)
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
Business Wire - Tue Apr 14, 3:22PM CDT
Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced that it intends to offer to sell $60 million of shares of its common stock in an underwritten public offering. As part of this offering, Akebia Therapeutics, Inc. intends to grant the underwriters a 30-day option to purchase up to an additional $9 million of shares of its common stock.
AKBA: 8.67 (-0.08), MS: 37.36 (-0.02)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), ZSPH: 40.97 (-1.90), RPTP: 10.81 (+0.10), OPK: 14.83 (+0.17), AMGN: 167.91 (-1.26), RGLS: 17.49 (-0.80), AMAG: 60.01 (-0.34), AKBA: 8.67 (-0.08), KERX: 11.41 (-0.32)
Akebia Therapeutics (AKBA) in Focus: Stock Slumps 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:00AM CDT
Akebia Therapeutics' shares fell over 14% last day reversing the uptrend as the stock had gained around 9% from Mar 25 to Mar 31
ARQL: 2.12 (unch), AKBA: 8.67 (-0.08)
Akebia Therapeutics' (AKBA) CEO John Butler discusses the results of its Phase 2b study of AKB-6548CEO (Transcript)
SA Transcripts - at Seeking Alpha - Mon Mar 16, 2:24PM CDT
AKBA: 8.67 (-0.08)
